A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

This study is comparing a combination of JMT101 (an EGFR-targeting antibody) plus osimertinib versus osimertinib alone as first-line treatment for advanced non-small cell lung cancer (NSCLC) with an EGFR mutation — a specific genetic change that the cancer depends on to grow. **You may be eligible if...** - You are 18 years of age or older - You have advanced or metastatic non-squamous NSCLC (Stage IIIB, IIIC, or IV) - Your cancer has an EGFR mutation (confirmed by testing) - You have not received any prior systemic treatment for your advanced lung cancer **You may NOT be eligible if...** - You have received prior treatment for advanced lung cancer - Your cancer does not have an EGFR mutation - Your general health is too poor to tolerate treatment Talk to your doctor to see if this trial is right for you.